Skip to content

CMR Features in Patients With Suspected Myocarditis

Predictive Value of CMR Features in Patients With Suspected Myocarditis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03470571
Acronym
CMRMyo
Enrollment
670
Registered
2018-03-20
Start date
2016-06-01
Completion date
2018-02-01
Last updated
2018-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Outcome, Fatal

Brief summary

Presentation of myocarditis is heterogeneous, often ranges from being asymptomatic, to chest pain, dyspnoea, palpitations, and even sudden cardiac death. Diagnosing myocarditis is challenging with no current uniform clinical gold-standard. CMR is a key investigative tool, however the predictive value of CMR features is unknown. In this study we assess 670 consecutive patients with suspected myocarditis who were referred for CMR between 2002 and 2015 at the BWH. CMR features such as late gadolinium sizing, T1 mapping, extracellular volume fraction assessment, strain analysis (feature tracking), clinical data, labortory tetsings and electrocardiogramm are linked to the outcome in order to assess its predictive value.

Interventions

DIAGNOSTIC_TESTCMR

Outcome analysis of CMR features in suspected myocarditis patients

Sponsors

Brigham and Women's Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients referred by their treating physician to undergo CMR for suspected myocarditis as the primary clinical question

Exclusion criteria

* evidence of coronary artery disease * hypertrophic cardiomyopathy * arrhythmogenic right ventricular cardiomyopathy * cardiac sarcoidosis * cardiac amyloidosis * takotsubo cardiomyopathy * constrictive pericarditis * Loeffler endocarditis * ventricular non-compaction * cardiac tumor * pulmonary embolism * severe valve disease

Design outcomes

Primary

MeasureTime frameDescription
Major adverse cardiac eventsthrough study completion, an average of 2 yearsHeart failure hospitalization; all cause death; sustained ventricular arrhythmia; recurrent myocarditis; transplantation

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 26, 2026